Relugolix
- Generic Name
- Relugolix
- Brand Names
- Myfembree, Orgovyx
- Drug Type
- Small Molecule
- Chemical Formula
- C29H27F2N7O5S
- CAS Number
- 737789-87-6
- Unique Ingredient Identifier
- P76B05O5V6
- Background
Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under the brand name Orgovyx, for the treatment ...
- Indication
适用于治疗成年晚期前列腺癌症患者。
- Associated Conditions
- Advanced Hormone Sensitive Prostate Cancer, Advanced Prostate Cancer, Heavy Menstrual Bleeding, Severe Pain
- Associated Therapies
- -
Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
- Conditions
- Interventions
- First Posted Date
- 2018-11-23
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Myovant Sciences GmbH
- Target Recruit Count
- 229
- Registration Number
- NCT03751124
- Locations
- 🇺🇸
Houston, Houston, Texas, United States
🇺🇸Durham, Durham, North Carolina, United States
🇭🇺Nyíregyháza, Nyíregyháza, Hungary
SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain
- Conditions
- Interventions
- First Posted Date
- 2018-08-31
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- Myovant Sciences GmbH
- Target Recruit Count
- 802
- Registration Number
- NCT03654274
- Locations
- 🇺🇸
Park Ridge, Park Ridge, Illinois, United States
🇺🇸Corpus Christi, Corpus Christi, Texas, United States
🇺🇸Dallas, Dallas, Texas, United States
LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
- Conditions
- Interventions
- First Posted Date
- 2018-01-29
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Myovant Sciences GmbH
- Target Recruit Count
- 477
- Registration Number
- NCT03412890
- Locations
- 🇺🇸
Chicago, Chicago, Illinois, United States
🇺🇸Houston, Houston, Texas, United States
🇺🇸Miami, Miami, Florida, United States
SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain
- Conditions
- Interventions
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2021-06-28
- Lead Sponsor
- Myovant Sciences GmbH
- Target Recruit Count
- 623
- Registration Number
- NCT03204331
- Locations
- 🇺🇸
Aventura, Aventura, Florida, United States
🇺🇸Hialeah, Hialeah, Florida, United States
🇺🇸Idaho Falls, Idaho Falls, Idaho, United States
SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain
- Conditions
- Interventions
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2021-06-28
- Lead Sponsor
- Myovant Sciences GmbH
- Target Recruit Count
- 638
- Registration Number
- NCT03204318
- Locations
- 🇺🇸
Miami, Miami, Florida, United States
🇺🇸Seattle, Seattle, Washington, United States
🇺🇸San Diego, San Diego, California, United States
LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
- First Posted Date
- 2017-04-06
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- Myovant Sciences GmbH
- Target Recruit Count
- 382
- Registration Number
- NCT03103087
- Locations
- 🇺🇸
Dallas, Dallas, Texas, United States
🇿🇦Cape Town, Cape Town, Western Cape, South Africa
🇨🇿Ostrava, Ostrava, Czechia
A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer
- First Posted Date
- 2017-03-21
- Last Posted Date
- 2022-01-18
- Lead Sponsor
- Myovant Sciences GmbH
- Target Recruit Count
- 1134
- Registration Number
- NCT03085095
- Locations
- 🇺🇸
Greensboro, Greensboro, North Carolina, United States
🇺🇸Albany, Albany, New York, United States
🇺🇸Syracuse, Syracuse, New York, United States
LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
- First Posted Date
- 2017-02-10
- Last Posted Date
- 2022-04-19
- Lead Sponsor
- Myovant Sciences GmbH
- Target Recruit Count
- 388
- Registration Number
- NCT03049735
- Locations
- 🇺🇸
Clearwater, Clearwater, Florida, United States
🇺🇸Hialeah, Hialeah, Florida, United States
🇺🇸Chattanooga, Chattanooga, Tennessee, United States
A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids
- Conditions
- Interventions
- First Posted Date
- 2016-01-13
- Last Posted Date
- 2019-03-22
- Lead Sponsor
- Takeda
- Target Recruit Count
- 281
- Registration Number
- NCT02655237
A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids
- First Posted Date
- 2016-01-13
- Last Posted Date
- 2019-03-22
- Lead Sponsor
- Takeda
- Target Recruit Count
- 65
- Registration Number
- NCT02655224
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.